tiprankstipranks
The Fly

Neurocrine initiates Phase 3 registrational program for osavampator in MDD

Neurocrine initiates Phase 3 registrational program for osavampator in MDD

Neurocrine (NBIX) initiated a Phase 3 registrational study to evaluate the efficacy, safety and tolerability of osavampator, an investigational drug under development as an adjunctive treatment to antidepressants for major depressive disorder, or MDD. Positive topline data for the Phase 2 SAVITRI study of osavampator in adult subjects with MDD were announced in April 2024. The Phase 2 SAVITRI study with osavampator met its primary and secondary endpoints, and was generally well tolerated. Neurocrine received an exclusive license to osavampator from Takeda Pharmaceutical for all indications in all territories worldwide except Japan.

Discover the Best Stocks and Maximize Your Portfolio:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1